Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Front Oncol ; 14: 1337521, 2024.
Article in English | MEDLINE | ID: mdl-38720806

ABSTRACT

This study investigates breast cancer survival rates between 2000 and 2022 in northern Israel, focusing on ethnicity, socioeconomic status, age at diagnosis, and the Charlson Comorbidity Index. Analyzing data from Clalit Health Services, we studied 8,431 breast cancer patients (6,395 Jewish, 2,036 Arab). We compared five- and ten-year survival rates across different demographics. Ethnicity showed a minor impact on survival (OR 1.12, 95% CI: 0.93 - 1.35). Socioeconomic status had a significant effect, with a higher level of improving survival (OR 2.50, 95% CI: 2.04 - 3.08). Age was crucial; women 18-39 had better survival than 60-100, but no significant difference was found between the 18-39 and 40-59 age groups [OR (CI 0.90 - 1.53, p = 0.231)]. For the Charlson Comorbidity Index, women with scores of 3-10 showed lower survival compared to scores of 0 and 1-2. There was a notable improvement in five-year survival rates among patients aged 18-59 diagnosed from 2009-2018 (90.7%) compared to 2000-2008 (86.9%) (p = 0.0046), but not in patients aged 60-100. The study highlights that socioeconomic status, age, and comorbidity scores are significant in determining survival rates for breast cancer. The improvement in survival rates for younger patients diagnosed more recently reflects advancements in treatment and care. This research provides valuable insights into the factors affecting breast cancer survival rates, underscoring the role of socioeconomic status, age, and comorbidities while also highlighting the progress in breast cancer treatment over recent years.

2.
J Immunother ; 47(4): 117-122, 2024 May 01.
Article in English | MEDLINE | ID: mdl-37909180

ABSTRACT

Metabolic pathways may regulate responses to cancer immunotherapy (IO). Due to its immunomodulatory properties, we sought to examine the association between serum vitamin B12 (VitB12) and survival in individuals with cancer treated with immune checkpoint inhibitors, compared with biological and chemotherapy. We collected data on patients with advanced cancer initiating intravenous antineoplastic treatment and a concomitant VitB12 measurement (elevated: >820 ng/L), between January 2010 and January 2022. Patients on IO and other regimens (control) were compared using the Mann-Whitney test for continuous variables, χ 2 test or Fisher test for categorical variables, and multivariate Cox regression models assessed the effect of VitB12 on overall survival and progression-free survival, adjusting for confounders. Patient groups (control: n = 408; IO: n = 93) were balanced for the treatment line and VitB12 (elevated 29.9% vs 23.7%; mean 762.4 vs 687.6 ng/L). In multivariate analysis, overall survival in all patients was negatively associated with VitB12 [control: hazard ratio (HR): 1.4, 95% CI: 1.01-1.96, P = 0.04, false discovery rate (FDR): 0.069; IO: HR: 2.74 as sum of linear baseline and interaction effects, log scale], age (HR: 1.03, 95% CI: 1.02-1.04, P < 0.01), male sex (HR: 0.66, 95% CI: 0.50-0.88, P < 0.01), and neutrophil-to-lymphocyte ratio (HR: 1.05, 95% CI: 0.48-0.99, P = 0.01). However, VitB12 was significantly negatively associated with progression-free survival only in the IO group ( P < 0.001, FDR < 0.001, calculated HR: 8.34; biological treatment P = 0.08; FDR: 0.111; neutrophil-to-lymphocyte ratio, P = 0.07; FDR: 0.09). Taken together, elevated VitB12 was a negative predictor for outcomes on IO, independently of other known prognostic factors. Further research is needed to elucidate the immune-metabolic interplay and its interaction with the gut microbiome, as well as interventional strategies to enhance IO responses.


Subject(s)
Antineoplastic Agents , Neoplasms , Humans , Male , Neoplasms/drug therapy , Antineoplastic Agents/therapeutic use , Progression-Free Survival , Immunotherapy , Vitamin B 12/therapeutic use , Retrospective Studies
3.
Article in English | MEDLINE | ID: mdl-36718280

ABSTRACT

Cyclin-dependent kinase (CDK) 4/6 inhibitors given with endocrine therapy are standard of care for the treatment of women with advanced hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER-2) negative breast cancer. Ribociclib is a CDK 4/6 inhibitor with moderate to solid inhibition of CYP3A4, a member of the cytochrome P450 family oxidase system, which may lead to interactions with medicinal substrates that are metabolized via CYP3A4. Statins are among the most widely prescribed medications worldwide, predominantly metabolized by the CYP3A4 isoenzyme. Rhabdomyolysis is a known rare side effect of statins, commonly triggered by drug interactions. We report a case of a 73-year-old woman with metastatic HR-positive and HER-2 negative breast cancer who developed rhabdomyolysis and acute kidney injury due to interaction between simvastatin and ribociclib with a literature review.

4.
Mol Clin Oncol ; 14(6): 120, 2021 Jun.
Article in English | MEDLINE | ID: mdl-33903826

ABSTRACT

A 63-year-old man was hospitalized for immune check-point inhibitors (ICIs) medicated pneumonitis, secondary to treatment with pembrolizumab for non-small cell lung cancer. He was treated with high dose steroids, mycophenolate mofetil, empiric broad spectrum antibiotics and empiric trimethoprim-sulfamethoxazole and intravenous immunoglobulin. Despite the aforementioned treatment, his condition continued to deteriorate. The patient was admitted to the intensive care unit. While intubated, he underwent bronchoscopy and lavage, which was analyzed for potential infectious agents. Cytomegalovirus (CMV) pneumonia was diagnosed and treated. He passed away despite antiviral treatment and maximal supportive care. CMV infection should be suspected in patients failing to recover from toxicities of ICIs with appropriate immunosuppression.

5.
J Adhes Dent ; 18(4): 303-9, 2016.
Article in English | MEDLINE | ID: mdl-27419239

ABSTRACT

PURPOSE: To determine the influence of aging in artificial saliva compared to distilled water on the dentin microtensile bond strength (µTBS) of different adhesive systems. MATERIALS AND METHODS: Occlusal enamel and superficial dentin of 42 teeth were removed and roots were sectioned to expose the pulp chamber for connecting the tooth segments to an intrapulpal pressure assembly. According to the tested adhesives, tooth segments were allocated to three groups (n = 14): an etch-and-rinse adhesive (Adper Scotchbond Multi-Purpose, SBMP), a two-step self-etching adhesive (Clearfil SE Bond, CSE), and a singlestep self-etching adhesive (Clearfil S3 Bond, S3). Each adhesive system was applied to the dentin surface according to its manufacturer's instructions, while intrapulpal pressure was simulated. Resin composite (3M ESPE) was built up in two increments of 2 mm each. Each bonded specimen was sectioned to obtain eight sticks (0.8 ± 0.01 mm2). Sticks of each group were divided equally (n = 56) according to the storage solution, either distilled water or artificial saliva. For each storage solution, half of the sticks of each subgroup (n = 28) was stored for 24 h at 37°C and the other half was thermocycled for 10,000 cycles between 5°C and 55°C. Sticks were then subjected to µTBS testing. Data were statistically analyzed using multifactor ANOVA with repeated measures and Bonferroni's post-hoc test (p < 0.05). Student's t-test was used for pairwise comparison. Failure modes were determined for all tested sticks using scanning electron microscopy. RESULTS: The decrease in bond strength of the three adhesives was significantly higher in distilled water than in artificial saliva. The predominant failure modes were adhesive and mixed. CONCLUSION: The decrease in bond strength was more pronounced for specimens stored in distilled water than in artificial saliva.


Subject(s)
Dental Bonding , Dentin-Bonding Agents/chemistry , Saliva, Artificial/chemistry , Water/chemistry , Adhesiveness , Composite Resins/chemistry , Dental Materials/chemistry , Dental Pulp/physiology , Humans , In Vitro Techniques , Materials Testing , Microscopy, Electron, Scanning , Pressure , Resin Cements/chemistry , Stress, Mechanical , Surface Properties , Temperature , Tensile Strength , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...